Gastrointestinal Cancer | Specialty

Dr. Overman on the Impact of Nivolumab in mCRC

March 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Kelley Discusses the Rising Incidence of HCC

March 20th 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.

Dr. Tempero on Emerging Agents in Pancreatic Cancer

March 20th 2018

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.

Atezolizumab, Cobimetinib Combo Active in mCRC

March 19th 2018

Atezolizumab in combination with cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer.

Venook Highlights Impact of IDEA Trial in Colon Cancer

March 19th 2018

Alan P. Venook, MD, discusses the significance of the findings of the international IDEA study investigating doses of FOLFOX for patients with colon cancer.

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC

March 16th 2018

The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.

Dr. Kelley on Newly Approved Agents in HCC

March 15th 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).

Dr. Collisson Discusses Developments in Gastric Cancers

March 15th 2018

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the focus of clinical trial research and genetic testing in gastrointestinal (GI) cancers.

Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer

March 14th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Dr. Pishvaian on Implications of Entrectinib Study in Pancreatic Cancer

March 9th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the implications of a study of entrectinib in patients with metastatic pancreatic cancer.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC

March 7th 2018

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.

FDA Approves 4-Week Nivolumab Dosing Schedule

March 6th 2018

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Nut Consumption Linked to Survival Benefit in Colon Cancer

March 3rd 2018

Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

Dr. Bekaii-Saab Discusses PEGPH20 in Pancreatic Adenocarcinoma

March 2nd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

Limitations in the Management of NETs

March 1st 2018

Developments in the NETs Treatment Landscape

March 1st 2018

Role of PRRT in the Management of NETs

March 1st 2018

Deciding on SSA Treatment in NETs

March 1st 2018

Overview of Somatostatin Analogs for NETs

March 1st 2018

Symptom Control in Functional NETs

March 1st 2018